Bayer HealthCare and Johns Hopkins University formed a five-year collaboration to develop treatments for eye diseases.
Bayer and the Wilmer Eye Institute of Johns Hopkins said they will jointly conduct research. Both partners will contribute staff and infrastructure to support the project, and Bayer holds exclusive rights for any results of the collaboration.
Financial terms of the agreement were not disclosed.
The drugmaker and university will work to bring new treatments to market for age-related macular degeneration, diabetic macular edema, geographic atrophy, Stargardt’s disease and retinal vein occlusion.
Bayer currently sells Eylea, an age-related macular degeneration drug that brought in sales of $862 million in 2014.
